Nasal Epinephrine Approval Signals GMP Shifts for Delivery Reformulations

ARS Pharmaceuticals' FDA approval of neffy, a nasal epinephrine product, underscores a broader industry trajectory: established molecules are being repositioned through novel delivery platforms, and the manufacturing and regulatory implications for companies pursuing similar line extensions are substantial. For plant heads and QA directors evaluating reformulation strategies, the shift from injectable to intranasal delivery is not merely a commercial play; it introduces distinct process validation, facility design, and submission requirements that diverge significantly from legacy parenteral lines.

The neffy approval, granted in 2025, demonstrated that a well-characterized active ingredient like epinephrine can be brought to market through an alternative route of administration. For manufacturers considering analogous reformulations, the transition demands careful assessment of GMP readiness. Nasal spray manufacturing requires dedicated or segregated equipment, validated spray characterization methods, and device-drug combination product testing under 21 CFR Part 4, layering complexity onto what might otherwise appear to be a straightforward formulation change. Process validation protocols must account for dose uniformity through container life, plume geometry, and droplet size distribution, none of which are considerations in traditional autoinjector production.

From a regulatory standpoint, delivery reformulations of existing drugs typically require a full 505(b)(2) NDA pathway rather than a supplemental application, as the change in route of administration necessitates new clinical pharmacokinetic and, in many cases, efficacy data. ICH Q8 principles around pharmaceutical development and design space definition become central, as sponsors must demonstrate that the new formulation's critical quality attributes are understood and controlled. QA teams should anticipate heightened scrutiny on stability programs, particularly for combination products where device performance over shelf life is integral to drug delivery.

Richard Lowenthal, whose discussion with Pharmaceutical Executive explored whether reformulated drugs can compete with first-to-market products, highlighted that such delivery innovations can have significant consequences for the competitive landscape. For existing drug manufacturers, the strategic calculus involves weighing the capital investment in new manufacturing capabilities against the potential for differentiated market positioning. Regulatory affairs leads should note that early engagement with FDA through pre-IND or Type B meetings is advisable when the delivery mechanism fundamentally alters the product's risk-benefit profile.

The neffy case offers a concrete reference point for operations and quality leaders assessing whether their current facilities and quality systems, built around ICH Q10 pharmaceutical quality system principles, can accommodate novel delivery formats without extensive retrofitting. As more sponsors explore intranasal, transdermal, and other non-invasive delivery routes for legacy molecules, the manufacturing sector should expect a growing need for specialized analytical capabilities, device integration expertise, and cross-functional regulatory strategy well ahead of submission.